Latest:
Dr Lin on Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Yi Lin, MD, PhD, discuses cilta-cel vs standard of care in patients with lenalidomide-refractory multiple myeloma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ignace B. Vergote, MD, PhD
Latest:
Dr Vergote on the Efficacy of Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer
Ignace B. Vergote, MD, PhD, discusses the efficacy of tisotumab vedotin-tftv in patients with recurrent or metastatic cervical cancer, according to data from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628).
Erin Roesch, MD
Latest:
A Dynamic Treatment Landscape Emerges for Early-Stage TNBC
Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.
John Nakayama, MD
Latest:
FDA Approvals of Immunotherapy in Gynecology Oncology
In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.
Janeesh Sekkath Veedu, MBBS
Latest:
Dr Sekkath Veedu on Survival Outcomes With Surgery vs Chemoradiation in Stage IIIA NSCLC
Janeesh Sekkath Veedu, MBBS, discusses the survival advantage conferred by surgical-based treatment compared with definitive chemoradiation in patients with stage IIIA non–small cell lung cancer.
Anne P. O’Dea, MD
Latest:
Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer
Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.